Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Bianca Weinstock-GuttmanRobert A BermelGary CutterMark S FreedmanThomas P LeistXiaoye MaDeidre KileBruno MuschAnthony T RederJerry S WolinskyPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Consistent efficacy of OCR on clinical and magnetic resonance imaging (MRI) disease activity measures and progression was shown in patients with RRMS and a suboptimal response to prior DMTs; no new safety signals were observed.
Keyphrases
- disease activity
- multiple sclerosis
- magnetic resonance imaging
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- contrast enhanced
- juvenile idiopathic arthritis
- white matter
- computed tomography
- diffusion weighted imaging
- open label
- clinical trial
- stem cells
- randomized controlled trial
- smoking cessation